February 2017 Performance

It’s nice to be in positive territory after a disastrous January. The largest contribution to the February performance was Wafergen Biosystems, which finally closed. Actelion and Ariad Pharmaceuticals were also positive contributors. I did sell my position in Kate Spade (Ticker: KATE) a bit too early, but overall I am pleased with how things turned out. I continued to add to my position in Actelion (Ticker: ALIOY). I also initiated a position in Syngenta (Ticker: SYT) and looking for that to close within the next few months.

Right now, my only merger arb plays are Actelion (~ 22% position) and Syngenta (~ 6% position).

Here’s a snap shot of my current holdings with their weighting:

 

2017 Performance Year to Date = +5.22% with the running monthly returns as follows:

January -4.50%

February +10.18%